Home Epigenetics MLL inhibitor Revumenib (SNDX-5613) For research use only.

Revumenib (SNDX-5613)

Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.

Revumenib (SNDX-5613) Chemical Structure

Revumenib (SNDX-5613) Chemical Structure

CAS No. 2169919-21-3

Purity & Quality Control

Revumenib (SNDX-5613) Related Products

Biological Activity

Description Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Targets
menin-MLL binding [1]
0.15 nM(Ki)
In vitro
In vitro

SNDX-5613  has anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8). SNDX-5613 doesn't inhibit growth of HL-60, a promyelocytic leukemia cell line lacking an MLL rearrangement , indicating selective activity towards leukemic cells lines that harbor MLL-rearranged (MLLr) fusion proteins.<sup><a class="sref" href="#s_ref">[1]</a></sup>
Cell Research Cell lines MV4;11, RS4;11, MOLM-13, KOPN-8, HL-60
Concentrations 1-100 nM
Incubation Time 2 h
Method

Multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN- 8) was used to assess the antiproliferative activity of SNDX-5613 against MLLr cell lines by standard cell proliferation assay.
In Vivo
In vivo

SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 xenografts nude rats.<sup><a class="sref" href="#s_ref">[1]</a></sup>
Animal Research Animal Models MOLM-13 model rats
Dosages 5, 15, 50 mg/kg
Administration Oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06226571 Recruiting
Acute Myeloid Leukemias
Syndax Pharmaceuticals
 May 2024 Phase 1
NCT05731947 Recruiting
Colorectal Cancer|Solid Tumors
Syndax Pharmaceuticals
 April 4 2023 Phase 1|Phase 2
NCT05360160 Recruiting
Acute Myeloid Leukemia
M.D. Anderson Cancer Center|Astex Pharmaceuticals Inc.|Syndax Pharmaceuticals
 October 14 2022 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 630.82 Formula

C32H47FN6O4S
CAS No. 2169919-21-3 SDF --
Smiles CCN(C(C)C)C(=O)C1=C(OC2=CN=CN=C2N3CC4(CCN(CC4)CC5CCC(CC5)N[S](=O)(=O)CC)C3)C=CC(=C1)F
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 25 mg/mL ( (39.63 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 25 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Revumenib (SNDX-5613) | Revumenib (SNDX-5613) supplier | purchase Revumenib (SNDX-5613) | Revumenib (SNDX-5613) cost | Revumenib (SNDX-5613) manufacturer | order Revumenib (SNDX-5613) | Revumenib (SNDX-5613) distributor